Journals / Nöropsikiyatri Arşivi / 2011 / Cilt: 48 - Sayı: 2

Major depresyonlu hastada mirtazapine bağlı, geri dönüşümlü hepatotoksisite

Reversible hepatotoxicity of mirtazapine in a patient with major depression

Pages
162–163
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present a case of 23 years old female depressive patient who developed abdominal pain and elevation of liver enzymes during treatment with mirtazapine and returned to normal after stopping the mirtazapine use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Mirtazapine is a noradrenergic and specific serotonergic antidepressant that is approved for use in the treatment of major depression.
📊
Key Findings & Data:It is generally well tolerated with some mild side effects such as drowsiness, excessive sedation, increased appetite, weight gain, and dry mouth.
💡
Conclusion & Impact:We present a case of 23 years old female depressive patient who developed abdominal pain and elevation of liver enzymes during treatment with mirtazapine and returned to normal after stopping the mirtazapine use.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Mirtazapine is a noradrenergic and specific serotonergic antidepressant that is approved for use in the treatment of major depression. It is generally well tolerated with some mild side effects such as drowsiness, excessive sedation, increased appetite, weight gain, and dry mouth. We present a case of 23 years old female depressive patient who developed abdominal pain and elevation of liver enzymes during treatment with mirtazapine and returned to normal after stopping the mirtazapine use.

Özet

Mirtazapin, major depresyon tedavisinde onay almış, noradrenerjik ve spesifik serotonerjik bir antidepresandır. Sersemlik, aşırı sedasyon, iştahta artma, kilo alımı ve ağız kuruluğu gibi yan etkileri olabilmesine karşın genellikle iyi tolere edilir. Burada, 23 yaşında depresif kadın hastada, mirtazapin tedavisi sırasında gelişen karın ağrısı ve karaciğer enzimlerinde yükselme olması ve mirtazapin kullanımı durdurulduktan sonra bulguların normale dönmesi tartışılmıştır.

🔖

Cite This Article

DUMLU, T., CANAN, F., CELBEK, G., GÜNGÖR, A., AYDIN, Y. (2011). Major depresyonlu hastada mirtazapine bağlı, geri dönüşümlü hepatotoksisite. Nöropsikiyatri Arşivi, Cilt: 48 - Sayı: 2, 162–163. https://ajindex.com/articles/292680

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Marek GJ, Carpenter LL, McDougle CJ et al. Synergistic action of 5- HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003; 28:402-12
  2. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009; 23:427-52
  3. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995; 10:37-45
  4. Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol 2007; 45:45-50
  5. Hui CK, Yuen MF, Wong WM et al. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol 2002; 35:270-1
  6. Adetunji B, Basil B, Mathews M et al. Mirtazapine-associated dosedependent and asymptomatic elevation of hepatic enzymes. Ann Pharmacother 2007; 41:359
  7. Be´nichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11:272-6
  8. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45.